Healthcare
Vulcan leads $10.5m Series A for Singapore's Amili
Vulcan Capital, an investment vehicle established by Microsoft co-founder Paul Allen, has led a USD 10.5m Series A round for Singapore-based microbe analytics start-up Amili.
Deal focus: Singapore biotech start-up generates US buzz
Singapore’s Tessa Therapeutics has developed a cancer drug that appears to be twice as effective as other treatments in its class. It has raised USD 126m with eyes on a near-term US IPO
New Zealand deep-tech VC Pacific Channel seeks co-investors
Pacific Channel, which claims to be the largest deep-tech specialist in New Zealand’s venture capital industry, is seeking co-investors to support maturing portfolio companies that require additional capital.
Singapore cancer treatment start-up gets $126m Series A
Singapore’s Tessa Therapeutics, a biotech developer with a Hodgkin's lymphoma treatment in phase-two trials, has raised a USD 126m Series A round led by US healthcare specialist Polaris Partners.
Med-Fine leads Series A for China's Degron Therapeutics
US and China-based biotech player Degron Therapeutics has closed a USD 22m Series A round led by Med-Fine Capital.
Fengshi leads $45m Series D for China cancer diagnosis player
Singlera Genomics, a Shanghai-based cancer diagnostics specialist, has raised an extended Series B round of CNY 300m (USD 45m) led by Fengshi Investment Management.
China's Insilico Medicine gets $60m Series D
Insilico Medicine, a China-based artificial intelligence (AI)-driven drug discovery company, has raised a USD 60 million Series D round.
Japan's Luca Science secures $30m Series B
Luca Science, a Japanese biotech start-up focused on dysfunctional and damaged tissues and organs, has raised a USD 30.3m Series B round led by life sciences specialists 4BIO Capital and DCI Partners.
Malaysia's IHH Healthcare sells education arm to Rise Fund
A consortium led by The Rise Fund, TPG’s global impact investment platform, has agreed to acquire the medical education arm of Malaysia-headquartered IHH Healthcare for MYR 1.35bn (USD 306m).
Hong Kong's Saltagen targets $120m for biotech fund
Saltagen Ventures, a Hong Kong-based venture capital firm led by Canada’s trade representative to the Asia Pacific Economic Cooperation (APEC) forum, is looking to raise USD 120m for a global biotech fund.
Sequoia leads Series A extension for China's ProfoundBio
Sequoia Capital China has led a USD 70m extended Series A round for ProfoundBio, a Chinese drug developer with two cancer treatments entering phase-one clinical trials.
Creador, InvAscent invest $68m in India medical supplier
Malaysia-based Creador and Indian healthcare specialist InvAscent have invested a combined USD 68m in Indian medical equipment supplier Accumax Lab Devices.
Fullerton reaches $100m first close on Thai PE fund
Singapore’s Fullerton Fund Management has hit a first close of USD 100m on its first Thai private equity strategy in partnership with KBank Private Banking, a division of local lender Kasikorn Bank.
Advent raises $25bn for global PE fund, targets China
Advent International has closed its largest ever global private equity fund at the hard cap of USD 25bn with plans to expand its investment activity in Greater China in the next few years.
Deal focus: ICG finds alignment with doctor-shareholders
Intermediate Capital Group believes its flexible approach to deal structuring – and a willingness to share upside – helped win over doctors who are employees and part-owners of Canopy Healthcare
MDI leads $27m round for Singapore's SwipeRx
Indonesia’s MDI Ventures has led a USD 27m Series B round for Singapore-based mClinica, now rebranded as SwipeRx, an app that connects 45,000 pharmacies across Southeast Asia.
Japan biotech start-up raises $31m Series C
Japanese cancer drug developer Chordia Therapeutics has raised JPY 4bn (USD 31.3m) in Series C funding led by Growth Capital of Japan (GCJ) and UTokyo Innovation Platform.
SPAC target Prenetics sinks on US debut
Hong Kong-based genomic and diagnostic testing business Prenetics slumped on its NASDAQ debut, unable to withstand struggling public markets public markets and weak investor appetite for businesses that merge with US-listed special purpose acquisition...
India's Multiples invests $88m in BDR Pharma
Multiples Private Equity has led a consortium in the acquisition of a 9.3% stake in India’s BDR Pharmaceuticals for INR 6.8bn (USD 88.5m).
Japan Industrial Solutions supports troubled local drug maker
Japan Industrial Solutions (JIS) has agreed to invest up to JPY 20bn (USD 155m) in Japan-based generic drug manufacturer Nichi-Iko Pharmaceutical with a view to saving the troubled company.
Eight Roads launches $250m India healthcare fund
Eight Roads Ventures has launched its first dedicated healthcare and life-sciences fund for India with a corpus of USD 250m provided entirely by its parent, Fidelity.
ICG buys New Zealand's Canopy Healthcare
ICG has acquired Canopy Healthcare Group, a New Zealand-based healthcare platform that offers diagnostic imaging, medical oncology, and drug compounding services.
PAG backs acquisition of India's Optimus Drugs
PAG has supported the acquisition of Optimus Drugs for an undisclosed sum alongside CX Partners and Samara Capital as part of a joint Indian pharmaceuticals platform play.
MDI launches healthcare fund with Indonesian strategic
MDI Ventures, the corporate VC arm of state-controlled Telkom Indonesia, has launched a USD 20m fund with domestic vaccine manufacturer Bio Farma that will pursue early and growth-stage healthcare investments.